First DKMS clinical trial has practice-changing results for patients with AML
In acute myeloid leukemia (AML), standard of care is to attempt a complete remission before stem cell transplantation. This imperative is now being challenged by the results of the first ever completed clinical trial facilitated and organized by DKMS. The trial was supported by the Study Alliance Leukemia (SAL), the Cooperative German Transplant Study Group, and the Gert and Susanna Mayer Foundation. The results of this trial suggest that adult patients that are dealing with relapse or refractory AML should receive stem cell transplantation as soon as possible. Contrary to earlier assumptions, achieving complete remission prior to transplantation does not increase the overall chances for life but even unnecessarily prolongs chemotherapy, associated side effects, and hospitalization. This important conclusion was reached by the researchers at the University Hospital Carl Gustav Carus Dresden, the National Center for Tumor Diseases Dresden (NCT/UCC), and the University Hospital Münster (Germany). Prof. Dr. Schetelig, Head of the Department of Stem Cell Transplantation at the University Hospital Dresden and Head of the DKMS Clinical Trials Unit, presented the results on December 11 at the world's largest hematology congress - the annual meeting of the American Society of Hematology (ASH) - in New Orleans, USA.
An updated version of this page is available.